Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEVLARx: RRx-001 for the Attenuation of Severe Oral Mucositis in Head and Neck Cancer
NCT05966194Phase 2Active, not recruiting
- Sponsor
- EpicentRx
- Start
- Apr 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Nibrozetone in oral mucositis (OM), sponsored by EpicentRx. Started Apr 2024; status: active, not recruiting.
02
Drugs
Nibrozetone
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT05966194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966194.